Đang chuẩn bị liên kết để tải về tài liệu:
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: A randomised trial

Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). |